Lanoteplase

Drug Profile

Lanoteplase

Alternative Names: BMS 200980; FEX 1; nPA; Oneplas; SUN 9216

Latest Information Update: 18 Jun 2002

Price : $50

At a glance

  • Originator Wyeth
  • Class Plasminogen activator enzymes; Thrombolytics
  • Mechanism of Action Plasminogen activators; Plasminogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ischaemic heart disorders; Myocardial infarction; Thrombosis

Most Recent Events

  • 18 Jun 2002 Discontinued - Preregistration for Myocardial infarction in Japan (Injection)
  • 26 Mar 2002 American Home Products and its subsidiary Wyeth-Ayerst are both now called Wyeth
  • 23 Jan 2001 Discontinued-III for Ischaemic heart disorders in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top